Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography.

ABSTRACT:

Introduction

Psoriasis is a chronic inflammatory disease associated with multiple systemic comorbidities and reduced quality of life. Risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in achieving rapid and sustained skin clearance in moderate-to-severe psoriasis. However, its impact on chronic subclinical inflammation is less understood. Conventional clinical assessments like Psoriasis Area and Severity Index (PASI), Investigator's Global Assessment (IGA), and Body Surface Area (BSA) focus on evaluating visible symptoms and are limited in capturing underlying disease activity. Optical coherence tomography (OCT), a non-invasive imaging modality, offers real-time assessment of structural and vascular changes, providing valuable insights beyond the skin surfac

SUBMITTER: Zirpel H 

PROVIDER: S-EPMC12936233 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature